Methods of treating cancers associated with reduced expression of interleukin 1 [beta]
By modulating the NF-KB signaling pathway through the application of IRAK4 inhibitors or degraders, the expression of interleukin-1β and immediate early response gene 3 is reduced, which addresses the shortcomings of existing technologies in the treatment of non-Hodgkin's lymphoma, acute myeloid leukemia, and myelodysplastic syndromes, and improves the treatment effect.
Patent Information
- Application Number
- CN202480064154.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-10-27
- Filing Date
- 2024-10-25
- Publication Date
- 2026-05-01
AI Technical Summary
Current technologies lack effective treatments for cancers such as non-Hodgkin's lymphoma, acute myeloid leukemia, and myelodysplastic syndromes, especially those caused by overactivity of the NF-κB signaling pathway. Furthermore, existing immune checkpoint inhibitors do not respond consistently to all patients.
By applying IRAK4-modifying compounds, especially IRAK4 inhibitors or degraders such as emavusertib, the expression of NF-KB-related genes can be regulated, the expression of interleukin-1β and immediate early response gene 3 can be reduced, and the activity of IRAK4 can be inhibited, thereby affecting the NF-KB signaling pathway.
It significantly reduced the expression of interleukin-1β and immediate early response gene 3 in cancer patients, improving the treatment response rate for cancer, especially the clinical response in high-risk MDS and AML patients.